Compare · ARGX vs BCDA
ARGX vs BCDA
Side-by-side comparison of argenx SE (ARGX) and BioCardia Inc. (BCDA): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ARGX and BCDA operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
- ARGX is the larger of the two at $54.76B, about 5233.3x BCDA ($10.5M).
- Over the past year, ARGX is up 51.2% and BCDA is down 58.3% - ARGX leads by 109.6 points.
- BCDA has been more active in the news (11 items in the past 4 weeks vs 5 for ARGX).
- ARGX has more recent analyst coverage (25 ratings vs 1 for BCDA).
- Company
- argenx SE
- BioCardia Inc.
- Price
- $882.63-1.03%
- $0.95-8.65%
- Market cap
- $54.76B
- $10.5M
- 1M return
- +12.11%
- -13.64%
- 1Y return
- +51.24%
- -58.33%
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2017
- News (4w)
- 5
- 11
- Recent ratings
- 25
- 1
argenx SE
argenx SE, a clinical-stage biotechnology company, focuses on developing antibody-based therapies for the treatment of autoimmune diseases, hematology, and cancer. It is developing its lead product candidate, efgartigimod, for the treatment of patients with myasthenia gravis; immune thrombocytopenia in Phase III; pemphigus vulgaris in Phase III; chronic inflammatory demyelinating polyneuropathy in Phase III; and ENHANZE SC in pre-clinical stages. The company is also developing cusatuzumab in Phase II clinical stage in hematological cancer indications; ARGX-117 in phase I clinical trial with therapeutic potential in both orphan and large autoimmune inflammatory diseases; and preclinical products, including ARGX-118 for airway inflammation. Its partnered product candidates include ARGX-112 for treating skin inflammation, ARGX-116 for the treatment of dyslipidemia, and ARGX-115 for cancer immunotherapy, which are in Phase I clinical stages; and ARGX-114 for treating fibrosisand ARGX-119 for treating neuromuscular indications, which are in preclinical stage. The company has strategic partnership with AbbVie S.Ã.R.L. and LEO Pharma A/S; and collaboration agreement with Cilag GmbH International, Staten Biotechnology B.V., and Shire International GmbH. argenx SE was incorporated in 2008 and is based in Breda, the Netherlands.
BioCardia Inc.
BioCardia, Inc., a clinical-stage regenerative medicine company, develops therapeutics for cardiovascular diseases. Its lead therapeutic candidate is the CardiAMP Cell Therapy System for the treatment of heart failure and chronic myocardial ischemia; and ALLOGENEIC cell therapy for cardiac and pulmonary disease. The company is also developing ALLOGENEIC Cell Therapy System, an investigational culture expanded bone marrow derived mesenchymal cell therapy, which is in Phase I/II trial for the treatment of ischemic systolic heart failure. In addition, it offers the Helix biotherapeutic delivery system, a percutaneous catheter delivery system for cardiovascular regenerative medicine; and Morph deflectable guides and sheaths. The company is based in San Carlos, California.
Latest ARGX
- SEC Form 6-K filed by argenx SE
- argenx Presents New Efgartigimod Data Showing Long-Term Sustained Patient Benefit in Myositis and Sjogren's Disease at EULAR 2026
- argenx to Host Myositis R&D Webinar on June 23, 2026
- argenx to Present at Upcoming Investor Conferences
- The Biology Came First.
- SEC Form 6-K filed by argenx SE
- argenx Announces U.S. FDA Approval Expanding VYVGART and VYVGART Hytrulo for Use in All Adult Patients Living with gMG
- SEC Form 6-K filed by argenx SE
- argenx Reports First Quarter 2026 Financial Results and Provides Business Update
- argenx to Present at BofA Securities 2026 Health Care Conference
Latest BCDA
- BioCardia Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
- BioCardia Announces $4.4 Million Financing
- BioCardia Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- FDA Confirms CardiAMP HF II May Support Premarket Approval of CardiAMP Cell Therapy for Ischemic HFrEF
- BioCardia Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- BioCardia Announces Japan PMDA Record Of Advice Supports Regulatory Submission For Approval Of CardiAMP Cell Therapy For Ischemic Heart Failure
- President and CEO Altman Peter bought $1,570 worth of shares (1,700 units at $0.92), increasing direct ownership by 0.58% to 293,266 units (SEC Form 4)
- BioCardia Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- BioCardia Announces CardiAMP Chronic Myocardial Ischemia Trial Results Presented at EuroPCR Showed Durable Improvements in Exercise Tolerance with Reduced Angina Frequency
- BioCardia to Participate in a Fireside Chat at the Alliance Global Partners (A.G.P) Healthcare Company Showcase